R&D

NIH Establishes Monkey Model for MERS-CoV

NIH Establishes Monkey Model for MERS-CoV

Written by on August 26, 2014 in Featured on App, News, R&D with 0 Comments

An NIH study suggests that marmoset models are the optimum option for testing new drugs for MERS Scientists from the National Institutes of Health have found that the Middle East Respiratory (MERS) virus in marmosets provokes a very similar response to humans afflicted with MERS caused pneumonia. The doctors began testing MERS treatments on marmosets […]

Continue Reading

Exclusive vaccine delivery interview with Dr Chantal Pichon, University of Orleans and CNRS

Exclusive vaccine delivery interview with Dr Chantal Pichon, University of Orleans and CNRS

The 15th World Vaccine Congress on 13 – 15 October in Brussels is just a few weeks away and I recently sat down with one of our key speakers, Dr Chantal Pichon (Professor, University of Orleans and CNRS Center for Molecular Biophysics) for a short interview. Dr Pichon will be discussing her research in Histidylated-based […]

Continue Reading

Therapeutic

Japan May Provide West African Countries With Unapproved Ebola Treatment

Japan May Provide West African Countries With Unapproved Ebola Treatment

Written by on August 27, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

The Japanese government is ready to provide Ebola afflicted countries an experimental drug that has not yet been approved by the WHO On Monday the 27th of August, Japan’s Chief Cabinet Secretary Yoshihide Suga announced that the country is willing to donate a flu drug called Favipiravir to aid the Ebola crisis in west Africa. […]

Continue Reading

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Written by on August 22, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer […]

Continue Reading

Prophylactic

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

Written by on August 26, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

A vaccine resistant mutation of the poliovirus was the cause of the major 2010 polio outbreak in DR Congo Research published in the scientific journal ‘Proceedings of the National Academy of Sciences‘ has shown that a mutated strain of the poliovirus was responsible for a 2010 outbreak in the Democratic Republic of Congo, which claimed […]

Continue Reading

New Vaccine Provides Greater Protection than BCG Against Both Tuberculosis and Leprosy

New Vaccine Provides Greater Protection than BCG Against Both Tuberculosis and Leprosy

Written by on August 22, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

Research headed by UCLA has found that a variation of the BCG vaccine offers stronger protection against the diseases Both tuberculosis and leprosy often occur together, and leprosy usually only occurs in places where tuberculosis occurs. Most infants are vaccinated against the two diseases with the Bacille Calmette-Guerin vaccination, which has been used for over […]

Continue Reading

Flu

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

Written by on August 27, 2014 in Antibodies, Featured on App, Flu, News with 0 Comments

Research suggests that vaccinations against rare strains of bird flu would be highly effective against a broad range of influenza viruses A study by the Emory Vaccine Centre in Atlanta has found that exposure to rare and uncommon flu strains results in the production of broadly effective antibodies. The study thus begs the question: should […]

Continue Reading

FDA Approves AFLURIA Flu Vaccine To Be Administered With Pharmajet’s Needle-Free Injector

FDA Approves AFLURIA Flu Vaccine To Be Administered With Pharmajet’s Needle-Free Injector

Written by on August 22, 2014 in Featured on App, Flu, News with 0 Comments

The future of vaccine administration my change forever with Pharmajet’s needle-free injector The FDA has approved the first needle-free drug system for the delivery of bioCSL’s influenza vaccine AFLURIA. Now, doctors and other health care workers can chose whether they want to administer the influenza vaccine via a needle or through PharmaJet’s needle-free system. Ron […]

Continue Reading

Regulation & Policy

Focus on the Children: New study finds key to improving vaccine coverage

Focus on the Children: New study finds key to improving vaccine coverage

Written by on August 22, 2014 in Regulation and Policy with 0 Comments

A new report shows the power of child orientated pro-vaccine messages when trying to convince parents to vaccinate their children A new study, published earlier this month in Pediatrics, has shown that, when trying to convince parents of young children, that emphasizing the benefits to their infant is more effective than pushing home the societal benefits of […]

Continue Reading

FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

FDA Enables Potential Use of Experimental Tekmira Vaccine on Ebola Patients

Written by on August 11, 2014 in Featured on App, Regulation and Policy with 0 Comments

On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients The FDA has lifted a temporary ‘halt in research’ placed on the Ebola drug that has been developed by Canadian company Tekmira Pharmaceuticals. The lift of this hold means that the experimental […]

Continue Reading

Emerging Markets

The State of the Art of Electronic Health Records – Infographic

The State of the Art of Electronic Health Records – Infographic

Written by on August 22, 2014 in Emerging Markets, News with 0 Comments

In the next 10 years, data science and software will do more for medicine than all of the biological sciences together” Vinod Khosla, venture capitalist Last year, Vaccine Nation reported on research suggesting that the adoption of Electronic Health Records (EHR) could dramatically increase the ability of public health authorities to track immunizations amongst patient. […]

Continue Reading

Ebola Treatment Centre: An Interactive Guide

Ebola Treatment Centre: An Interactive Guide

Written by on August 19, 2014 in Emerging Markets, Featured on App, News with 0 Comments

The Golden Number: 42 Days With a while to wait before we see an approved Ebola vaccine become available, the virus must be effectively contained in order to see an end to the outbreak. The time it takes for symptoms to appear after exposure to the virus is known as the incubation period – and […]

Continue Reading

Supply Chain

Lost Small Pox Vials and Anthrax Mishaps

Lost Small Pox Vials and Anthrax Mishaps

Written by on July 15, 2014 in News, Regulation and Policy, Supply Chain with 0 Comments

  Will small pox and anthrax biosafety concerns undermine vital research? Last week the US Centres for Disease Control and Prevention announced that 6 small pox vials had been discovered on the 1st of July during the clearing out of an old laboratory at the Nationality Institute of Health’s (NIH) Bethesda campus, Maryland. The six […]

Continue Reading

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Written by on June 25, 2014 in Features & Downloads, Supply Chain with 0 Comments

Frank Appel, Senior Manager, Europe Vaccines Segments, Process Solutions, Merck Millipore joined us last year at the World Vaccine Congress Europe to present on ‘Ensuring Critical Vaccine Supply: Raw Materials Perspective.’ Download this presentation now to find out more about: Ensuring Safety: A real challenge & business risk The Reality of Upstream Contamination BioSafety Strategy […]

Continue Reading

Strategy and Partnering

Pfizer Buys Baxter’s Vaccine Unit For $635 million

Pfizer Buys Baxter’s Vaccine Unit For $635 million

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International’s Vaccines Unit Worth $635 Million The deal will give Pfizer access to Baxter’s meningitis and encephalitis vaccine. Pfizer will also get access to part of a Baxter’s production facility in Austria, where the vaccines are made. The deal is expected to be carried and closes […]

Continue Reading

How to choose your perfect CRO partner

How to choose your perfect CRO partner

Deciding upon the correct CRO is a crucial element of each vaccine’s development for the likes of biotech’s and pharma, concerned with outsourcing their research. This eBook answers the all-important question of how to choose your perfect CRO partner by providing a checklist of the top 10 criteria that sponsors use for selecting CROs. Thereby […]

Continue Reading

Other Recent Posts

CDC Responds to #CDCwhistleblower Claims

CDC Statement Regarding 2004 Pediatrics Article, “Age at First Measles-Mumps-Rubella Vaccination in Children With Autism and School-matched Control Subjects: A Population-Based Study in Metropolitan Atlanta” CDC shares with parents and others great concern about the number of children with autism spectrum disorder. CDC is committed to continuing to provide essential data on autism, search for […]

Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

August 25th, 2014 Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will […]

Continue Reading

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Award Recognizes Significant Potential of Vaxxas’ Nanopatch Vaccines and Immunotherapies August 26th, 2014 Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, has been named a 2015 Technology Pioneer by the World Economic Forum. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform […]

Continue Reading

Top
Geolocation